Table 1.
Demographic and clinical characteristicsa
| Variables | Ciprofloxacin-susceptible E. coli (n = 216) | Ciprofloxacin-resistant E. coli (n = 39) | P value |
|---|---|---|---|
| Initial assessment in emergency room | |||
| Age (yr) (mean ± SD) | 51.9 (±17.8) | 61.4 (±16.5) | 0.002 |
| Diabetes | 40 (18.5) | 7 (17.9) | 1.000 |
| Previous UTI history (>3 months) | 53 (24.5) | 14 (35.9) | 0.176 |
| Acute pyelonephritis | 12 (5.6) | 5 (12.8) | |
| Cystitis | 41 (19.0) | 9 (23.1) | |
| Duration of prehospital illness (days) (mean ± SD) | 4.9 (±4.8) | 4.1 (±3.1) | 0.289 |
| Bacteremia | 73 (33.8) | 11 (28.2) | 0.581 |
| During follow-up assessment | |||
| Days to first follow-up from initial treatment | |||
| For patients initially not admitted | 5.5 | 5.1 | 0.485 |
| For patients initially admitted | 3.1 | 3.9 | 0.145 |
| Hospitalization | 46 (21.3) | 13 (33.3) | 0.147 |
| Duration (days) (mean ± SD) | 7.8 (±3.1) | 8.2 (±5.0) | 0.692 |
| Duration of therapy (days) (mean ± SD) | 13.2 (±4.0) | 14.9 (±5.0) | 0.018 |
| Adverse drug events | 10 (4.6) | 2 (5.1) | 1.000 |
a
Data represent numbers of participants (% of total) unless otherwise indicated.